Page 6 of 10 – SEC Filing Item 1(a) Name of Issuer
Inotek Pharmaceuticals Corporation
Item 1(b) Address of Issuer’s Principal Executive Offices
91 Hartwell Avenue, Lexington, MA 02421
Item 2(a) Name of Person Filing
This Schedule 13G is being jointly filed by Citadel Advisors LLC (“Citadel Advisors”), Citadel Advisors Holdings II
LP (“CAH2”), Citadel GP LLC (“CGP”) and Mr. Kenneth Griffin (collectively with Citadel Advisors, CAH2
and CGP, the “Reporting Persons”) with respect to shares of common stock (and options to purchase and/or other securities
convertible into common stock) of the above-named issuer owned by Citadel Equity Fund Ltd., a Cayman Islands limited company (“CEF”),
and Citadel Securities LLC, a Delaware limited liability company (“Citadel Securities”).
Citadel Advisors is the portfolio manager for CEF. CAH2 is the managing member of Citadel Advisors. CALC III LP, a Delaware
limited partnership (“CALC3”), is the non-member manager of Citadel Securities. CGP is the general partner of CALC3
and CAH2. Mr. Griffin is the President and Chief Executive Officer of, and owns a controlling interest in, CGP.
The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner
of any securities covered by the statement other than the securities actually owned by such person (if any).
Item 2(b) Address of Principal Business Office
The address of the principal business office of each of the Reporting Persons is c/o Citadel LLC, 131 S. Dearborn Street, 32nd
Floor, Chicago, Illinois 60603.
Item 2(c) Citizenship
Each of Citadel Advisors and CGP is organized as a limited liability company under the laws of the State of Delaware. CAH2 is
organized as a limited partnership under the laws of the State of Delaware. Mr. Griffin is a U.S. citizen.
Item 2(d) Title of Class of Securities
Common stock, $0.01 par value
Item 2(e) CUSIP Number
45780V102
| Item 1(a) | Name of Issuer |
Inotek Pharmaceuticals Corporation
| Item 1(b) | Address of Issuer’s Principal Executive Offices 91 Hartwell Avenue, Lexington, MA 02421 |
| Item 2(a) | Name of Person Filing This Schedule 13G is being jointly filed by Citadel Advisors LLC (“Citadel Advisors”), Citadel Advisors Holdings II LP (“CAH2”), Citadel GP LLC (“CGP”) and Mr. Kenneth Griffin (collectively with Citadel Advisors, CAH2 and CGP, the “Reporting Persons”) with respect to shares of common stock (and options to purchase and/or other securities convertible into common stock) of the above-named issuer owned by Citadel Equity Fund Ltd., a Cayman Islands limited company (“CEF”), and Citadel Securities LLC, a Delaware limited liability company (“Citadel Securities”). |
| Citadel Advisors is the portfolio manager for CEF. CAH2 is the managing member of Citadel Advisors. CALC III LP, a Delaware limited partnership (“CALC3”), is the non-member manager of Citadel Securities. CGP is the general partner of CALC3 and CAH2. Mr. Griffin is the President and Chief Executive Officer of, and owns a controlling interest in, CGP. |
| The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any). |
| Item 2(b) | Address of Principal Business Office The address of the principal business office of each of the Reporting Persons is c/o Citadel LLC, 131 S. Dearborn Street, 32nd Floor, Chicago, Illinois 60603. |
| Item 2(c) | Citizenship Each of Citadel Advisors and CGP is organized as a limited liability company under the laws of the State of Delaware. CAH2 is organized as a limited partnership under the laws of the State of Delaware. Mr. Griffin is a U.S. citizen. |
| Item 2(d) | Title of Class of Securities Common stock, $0.01 par value |
| Item 2(e) | CUSIP Number 45780V102 |
Follow Rocket Pharmaceuticals Inc. (NASDAQ:RCKT)
Follow Rocket Pharmaceuticals Inc. (NASDAQ:RCKT)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
